US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

Xtrackers Nifty 500 India ETF

23.15

-0.0133-0.06%

Post-market: 23.12-0.0300-0.13%16:10 EDT

Volume:494

Turnover:11.43K

Market Cap:4.63M

PE:- -

High:23.15

Open:23.12

Low:23.12

Close:23.16

52wk High:27.40

52wk Low:20.52

Shares:200.00K

Float Shares:200.00K

Volume Ratio:0.63

T/O Rate:0.25%

Dividend:0.08

Dividend Rate:0.34%

ROE:--

ROA:--

PB:--

PE(LYR):- -

Loading ...

Overview Company News Filings

Telix 2026 Half-Year Results: Strong Commercial Execution and Momentum in Late-Stage Pipeline

Asia's Least Favored Stock Market Has Shifted, According to BofA Fund Manager Poll

Abbisko Wins China IND Nod for Pan-KRAS Cancer Drug ABSK211

Traders Report RBI Continues Selling Dollars to Bolster Rupee Exchange Rate

CARsgen Therapeutics Holdings (SEHK:2171) Gains On CT0596 IND Clearance, But Is The Valuation Too Rich

Simply Wall St.

Trump: University of Miami donates 1994 Ibogaine IND to accelerate treatment for veterans

Trump's Truth Social latest posts

Citi Expresses Optimism on Indian Equities, Adds Axis Bank to Top Picks List

Press Release: Enveric Biosciences Reports Financial Results and Provides Corporate Update for Second Quarter 2026

Skye Bioscience and Redx Pharma Announce Transaction Agreement and $125 Million in Financings

Vistagen Reports Fiscal Year 2027 First Quarter Financial Results and Corporate Update

Press Release: TuHURA Biosciences Reports Second Quarter 2026 Financial Results and Provides a Corporate Update

Press Release: Quantum BioPharma Strengthens Equity and Liquidity in Q2 2026 as FDA Approves Lucid-MS for Pivotal Phase 2 Clinical Trial

Market Participants Suggest RBI May Have Acted to Defense Rupee

Satellos Reports Second Quarter 2026 Financial Results and Highlights Company Progress

Press Release: Invivyd Reports Second Quarter 2026 Financial Results and Recent Business Highlights

Eikon Therapeutics Reports Second Quarter 2026 Financial Results and Provides Clinical Updates

Press Release: Acrivon Reports Second Quarter 2026 Financial Results and Highlights Upcoming 2026 Clinical Data Catalysts

Press Release: Longeveron Announces 2026 Second Quarter Financial Results and Provides Business Update

Kailera Reports Second Quarter 2026 Financial Results and Provides Business Updates

Press Release: ArriVent BioPharma Reports Second Quarter 2026 Financial Results

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://sg.tigeractivity.com/stock/IND/news?page=2"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"IND","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"IND\",,,,,undefined,":{"symbol":"IND","market":"US","secType":"STK","nameCN":"Xtrackers Nifty 500 India ETF","latestPrice":23.145,"timestamp":1788206400000,"preClose":23.1583,"halted":0,"volume":494,"hourTrading":{"tag":"盘后","latestPrice":23.115,"preClose":23.145,"latestTime":"16:10 EDT","volume":7,"amount":162.015,"timestamp":1788207004404,"change":-0.03,"changeRate":-0.001296,"amplitude":0},"delay":0,"changeRate":-0.0005743081314259241,"floatShares":200001,"shares":200001,"eps":0,"marketStatus":"Closed","change":-0.0133,"latestTime":"08-31 16:00:00 EDT","open":23.115,"high":23.145,"low":23.115,"amount":11430,"amplitude":0.001295,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":1,"ttmEps":0,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1788249600000},"marketStatusCode":5,"adr":0,"exchange":"NASDAQ","adjPreClose":23.1583,"sharesOutstanding":200001,"nav":23.107,"aum":4621406.79,"dividendRate":0.003409,"bidAskSpread":0,"postHourTrading":{"tag":"盘后","latestPrice":23.115,"preClose":23.145,"latestTime":"16:10 EDT","volume":7,"amount":162.015,"timestamp":1788207004404,"change":-0.03,"changeRate":-0.001296,"amplitude":0},"volumeRatio":0.628339},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"IND\",,,,,undefined,":{"symbol":"IND","floatShares":200001,"roa":"--","roe":"--","lyrEps":0,"volumeRatio":0.628339,"shares":200001,"dividePrice":0.0789,"high":23.145,"amplitude":0.001295,"preClose":23.1583,"low":23.115,"week52Low":20.515,"pbRate":"--","week52High":27.4,"institutionHeld":0,"latestPrice":23.145,"eps":0,"divideRate":0.003409,"volume":494,"delay":0,"ttmEps":0,"open":23.115,"prevYearClose":24.78,"prevWeekClose":23.1583,"prevMonthClose":22.885,"prevQuarterClose":22.88,"fiveDayClose":23.065,"twentyDayClose":23.01,"sixtyDayClose":22.2234},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/IND\",params:#limit:5,,,undefined,":[{"date":"2026-06-18","symbol":"IND","amount":0.07775,"announcedDate":null,"type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2026-06-18","defaultRemindTime":1781789400000,"name":"Xtrackers Nifty 500 India ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2026-06-26","payableDate":"2026-06-18","currency":"USD","dateTimestamp":1781755200000,"payDate":"2026-06-26"}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"IND\",market:\"US\",,,undefined,":[{"executeDate":"2026-06-18","recordDate":"2026-06-18","paymentDate":"2026-06-26","value":0.07775,"currency":"USD"}],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"IND\",market:\"US\",delay:false,,,undefined,":{},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"IND\",pageSize:20,pageCount:2,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2660474641","title":"Telix 2026 Half-Year Results: Strong Commercial Execution and Momentum in Late-Stage Pipeline","url":"https://stock-news.laohu8.com/highlight/detail?id=2660474641","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2660474641?lang=en_us&edition=fundamental","pubTime":"2026-08-20 08:32","pubTimestamp":1787185920,"startTime":"0","endTime":"0","summary":"MELBOURNE, Australia and INDIANAPOLIS, Aug.  20, 2026 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, \"Telix\") today announces its financial results for the period ended June","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/08/20/3348062/0/en/telix-2026-half-year-results-strong-commercial-execution-and-momentum-in-late-stage-pipeline.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4585","LU1223082519.USD","MAA","LU1223082196.USD","LU1223083913.SGD","ASX","LU0390134368.USD","BK4530","LU0029874061.USD","IND","GDXJ","LU0757428866.USD","BK4588","LU0128526141.USD","SPRE","BK4215","LU1815336091.USD","SGDM","BK4526","TMS","SIL","TLX","XME","BK4121","BK4017","CRL","BK4543","BK4139","IE00BFMHRM44.USD","BK4141","CDE"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1129083876","title":"Asia's Least Favored Stock Market Has Shifted, According to BofA Fund Manager Poll","url":"https://stock-news.laohu8.com/highlight/detail?id=1129083876","media":"Deep News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1129083876?lang=en_us&edition=fundamental","pubTime":"2026-08-19 17:07","pubTimestamp":1787130439,"startTime":"0","endTime":"0","summary":"A recent survey conducted by Bank of America among fund managers reveals a notable shift in regional sentiment, with India now overtaking Indonesia as the most underweighted equity market in Asia....","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["INDZ","AEF","XC","EQLT","XXCH","GLIN","FLIBF","MEMX","EPI","DFAE","RAYE","BK4585","HEEM","BBEM","MEM","XCEM","EET","INCO","BCHI","SCHE","RWEM","INDE","NDIA","SEEM","BK4523","INQQ","SMIN","DEXC","VEXC","STXE","QLVE","IOPP","SPEM","MFEM","PIN","XCNY","KEMX","AVEM","QEMM","IND","ASIA","XSOE","EEMV","SCIN","GIND","TAJX","PEMX","INDQ","BK4550","INDY","BK4588","BKEM","TEMX","FEMR","VEU","FLIN","NFTY","IMVP","EMES","EMXC","INDL","EEMA","TEMR","INDA","INDH","BKF"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660858414","title":"Abbisko Wins China IND Nod for Pan-KRAS Cancer Drug ABSK211","url":"https://stock-news.laohu8.com/highlight/detail?id=2660858414","media":"TIPRANKS","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2660858414?lang=en_us&edition=fundamental","pubTime":"2026-08-19 12:38","pubTimestamp":1787114321,"startTime":"0","endTime":"0","summary":"Abbisko Cayman Limited ( ($HK:2256) ) has provided an update. Abbisko Therapeutics has secured Investigational New Drug clearance from China’s Nati...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/abbisko-wins-china-ind-nod-for-pan-kras-cancer-drug-absk211?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/abbisko-wins-china-ind-nod-for-pan-kras-cancer-drug-absk211?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["IND"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1189195744","title":"Traders Report RBI Continues Selling Dollars to Bolster Rupee Exchange Rate","url":"https://stock-news.laohu8.com/highlight/detail?id=1189195744","media":"Deep News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1189195744?lang=en_us&edition=fundamental","pubTime":"2026-08-19 12:04","pubTimestamp":1787112277,"startTime":"0","endTime":"0","summary":"According to informed traders, the Indian central bank is actively selling US dollars in the domestic foreign exchange market to support the rupee's exchange rate. These traders requested anonymity...","market":"sg","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["UDN","IOPP","NFTY","IND","PIN","FLIN","INDE","BK4588","UUP","INDY","TAJX","SMIN","FLIBF","SCIN","INDA","GIND","INCO","IMVP","BK4523","INDL","INQQ","BK4585","EPI","NDIA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660494978","title":"CARsgen Therapeutics Holdings (SEHK:2171) Gains On CT0596 IND Clearance, But Is The Valuation Too Rich","url":"https://stock-news.laohu8.com/highlight/detail?id=2660494978","media":"Simply Wall St.","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2660494978?lang=en_us&edition=fundamental","pubTime":"2026-08-19 02:24","pubTimestamp":1787077458,"startTime":"0","endTime":"0","summary":"CARsgen Therapeutics Holdings (SEHK:2171) has drawn fresh attention after its allogeneic CAR T-cell candidate CT0596 received IND clearance from China’s National Medical Products Administration for relapsed or refractory multiple myeloma.\nSee our latest analysis for CARsgen Therapeutics Holdings.\nThe CT0596 IND clearance arrives as CARsgen Therapeutics Holdings trades at HK$14.7, with a 1 day share price return of 2.15% and a 90 day share price return down 16.62%. The 1 year total shareholder...","market":"nz","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-2171/carsgen-therapeutics-holdings-shares/news/carsgen-therapeutics-holdings-sehk2171-gains-on-ct0596-ind-c","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-2171/carsgen-therapeutics-holdings-shares/news/carsgen-therapeutics-holdings-sehk2171-gains-on-ct0596-ind-c","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK1574","BK1161","BK4539","02171","BK4007","LENZ","IND","BK1585","BK1587","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660949985","title":"Trump: University of Miami donates 1994 Ibogaine IND to accelerate treatment for veterans","url":"https://stock-news.laohu8.com/highlight/detail?id=2660949985","media":"Trump's Truth Social latest posts","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2660949985?lang=en_us&edition=fundamental","pubTime":"2026-08-19 00:57","pubTimestamp":1787072260,"startTime":"0","endTime":"0","summary":"President Donald Trump announced on August 18 that the University of Miami has donated its original 1994 Ibogaine Investigational New Drug (IND) application to the federal government, a move he said...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"724a78f70d7146f1ab07ec048eae1639","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://trumpstruth.org/statuses/40964","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IND","IND.AU","BK7095"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1180340970","title":"Citi Expresses Optimism on Indian Equities, Adds Axis Bank to Top Picks List","url":"https://stock-news.laohu8.com/highlight/detail?id=1180340970","media":"Deep News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1180340970?lang=en_us&edition=fundamental","pubTime":"2026-08-17 13:20","pubTimestamp":1786944032,"startTime":"0","endTime":"0","summary":"Citi has expressed a positive outlook on the Indian stock market, driven by better-than-expected first-quarter earnings and the Nifty 50 index trading near its long-term average valuation. Analysts...","market":"nz","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NFTY","PIN","LU2236285917.USD","BK4588","TFNS","LU0203345920.USD","IYF","FLIBF","INDA","LU2360032135.SGD","LU1366192091.USD","LU0128525689.USD","INDE","BK4523","INQQ","MNDmain","LU2125154778.USD","BK4559","BK4504","BK4534","LU1162221912.USD","GLIN","LU1668664300.SGD","FTXO","LU0980610538.SGD","LU1244550577.SGD","LU1244550221.USD","LU0203347892.USD","LU1506573853.SGD","LU0072461881.USD","IE00BSNM7G36.USD","LU2417539215.USD","LU1201861249.SGD","LU2456880835.USD","LU0162691827.USD","LU0314106906.USD","LU1791807156.HKD","INCO","161121","BK4207","LU0106831901.USD","LU0098860793.USD","C","LU0648001328.SGD","EPI","LU1244550494.USD","IND","LU1074936037.SGD","LU2125154935.USD","SMIN","LU0320765646.SGD","INDY","LU0130102774.USD","LU0310800965.SGD","LU2462157665.USD","LU0170899867.USD","LU1267930227.SGD","LU0130517989.USD","BK4566","INDL","LU0477156953.USD","SCIN","LU0052756011.USD","FLIN","BK4585","NDIA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659126775","title":"Press Release: Enveric Biosciences Reports Financial Results and Provides Corporate Update for Second Quarter 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2659126775","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659126775?lang=en_us&edition=fundamental","pubTime":"2026-08-15 04:05","pubTimestamp":1786737900,"startTime":"0","endTime":"0","summary":"EB-003 Development Highlights:--  Continued advancing IND-enabling studies supporting the planned. submission of an Investigational New Drug  application for EB-003. --  Reported preclinical data demonstrating that EB-003 consistently. exhibited a non-hallucinogenic profile in a highly sensitive. --  Announced promising results from preclinical in vitro experiments. indicating no photoreactive potential for EB-003, further derisking its. continued development as a potential treatment of neuropsychiatric. --  Initiated genotoxicity studies to evaluate the potential for EB-003 to. interact with DNA and cause genetic mutations, a critical measure of. --  Secured U.S. Patent No. 12,605,361 pertaining to the Company's EVM301. Series of molecules being developed as potential treatments for mental","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4585","ENVB","GDOC","BK4604","BK4555","HYLG","BK4007","03160","BK4099","IDNA","TM","BK4588","MEDX","NVIB","IND"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659142000","title":"Skye Bioscience and Redx Pharma Announce Transaction Agreement and $125 Million in Financings","url":"https://stock-news.laohu8.com/highlight/detail?id=2659142000","media":"GlobeNewswire","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659142000?lang=en_us&edition=fundamental","pubTime":"2026-08-14 21:33","pubTimestamp":1786714380,"startTime":"0","endTime":"0","summary":"Combined company to trade on Nasdaq and operate as Fibrx Therapeutics, a fibrosis-focused company led by the Redx management team and boardCompany’s lead program will be RXC008, Redx’s GI-restricted p","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/08/14/3345392/0/en/skye-bioscience-and-redx-pharma-announce-transaction-agreement-and-125-million-in-financings.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IND"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659914159","title":"Vistagen Reports Fiscal Year 2027 First Quarter Financial Results and Corporate Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2659914159","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659914159?lang=en_us&edition=fundamental","pubTime":"2026-08-14 20:32","pubTimestamp":1786710720,"startTime":"0","endTime":"0","summary":"Exploratory analyses of patients with very severe social anxiety disorder demonstrated nominally statistically significant improvement in recently reported clinical studies FDA engagement planned duri","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/08/14/3345334/0/en/vistagen-reports-fiscal-year-2027-first-quarter-financial-results-and-corporate-update.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LABU","IND","BK4585","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659616146","title":"Press Release: TuHURA Biosciences Reports Second Quarter 2026 Financial Results and Provides a Corporate Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2659616146","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659616146?lang=en_us&edition=fundamental","pubTime":"2026-08-14 19:45","pubTimestamp":1786707900,"startTime":"0","endTime":"0","summary":"TAMPA, Fla., Aug. 14, 2026 /PRNewswire/ -- TuHURA Biosciences, Inc.  , a Phase 3 immuno-oncology company developing novel therapeutics to overcome resistance to cancer immunotherapy, today reported financial results for the Company's second quarter ended June 30, 2026, and provided a corporate update.\"We have made significant progress in advancing all our programs forward and are positioned to continue driving towards several anticipated milestones targeted for the second half of the year,\" said Dr. James Bianco, President and CEO of TuHURA Biosciences. \"In the second half, we anticipate receiving safe-to-proceed feedback from FDA and to initiating our Phase 1b/2 trial of VISTA in mutNPM1 r/r AML, initiating our in vivo POC studies for MDSC Inhibitors , potentially receiving orphan drug designation in Merkel cell carcinoma  for IFx-2.0, and potentially receiving orphan drug designation in AML for TBS-2025. The recent $50 million term credit facility made available to us by our largest ","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4232","R","IND","BK4022","HURA","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659145865","title":"Press Release: Quantum BioPharma Strengthens Equity and Liquidity in Q2 2026 as FDA Approves Lucid-MS for Pivotal Phase 2 Clinical Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2659145865","media":"Dow Jones","labels":["corporation","productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659145865?lang=en_us&edition=fundamental","pubTime":"2026-08-14 19:00","pubTimestamp":1786705200,"startTime":"0","endTime":"0","summary":"US$9.5 million as of June 30, 2026, increased from US$4.1 million as of. -- Cash and cash equivalents nearly doubled to US$3.65 million, up from. -- Total shareholders' equity increased to US$6.09 million, up approximately. 19% from US$5.10 million at December 31, 2025, reflecting a strengthened. -- Working capital improved significantly to approximately US$1.66 million. as of June 30, 2026, up from approximately US$0.42 million at December. 31, 2025, indicating strengthened short-term liquidity and full coverage. -- Quick ratio of 1.19 as of June 30, 2026, compared to 1.06 as of December. divided by current liabilities), confirming robust liquidity even on a. December 31, 2025. Importantly, approximately 47% of current liabilities,items, reflecting the Company's strong balance sheet management.Reduced Cash Burn and Cost Discipline-- Total operating expenses decreased by 53% in the second quarter of 2026. compared to the same period in 2025, to US$2.29 million from US$4.85. -- General ","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"corporation,productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1791710582.SGD","LU1989772923.USD","BK4585","LU0390134368.USD","LU1244550577.SGD","LU1732800096.USD","LU0314104364.USD","IND","LU0912757837.SGD","NVIB","EQR","LU1244550221.USD","LU1244550494.USD","LCIZ","LU0006306889.USD","LU0053666078.USD","LU2133065610.SGD","LU0234570918.USD","LU0098860793.USD","BK4551","BK4596","BK4581","LU1732799900.SGD","LU2023251221.USD","LU0158827948.USD","BK4516","03160","LU0210528500.USD","LU2089283258.USD","LU2111349929.HKD","REZ","LCID","LU2264538146.SGD","IE00B775SV38.USD","LCDL","LU0106261372.USD","VMRK","BK4099","LU1791710400.SGD","LU2357305700.SGD","LU0267386448.USD","IAI","LU1548497426.USD","LU1988902786.USD","QNTM","BK4127","LU0795875169.SGD","LABU","KBWB","LU0106831901.USD","TM"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1155674567","title":"Market Participants Suggest RBI May Have Acted to Defense Rupee","url":"https://stock-news.laohu8.com/highlight/detail?id=1155674567","media":"Deep News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1155674567?lang=en_us&edition=fundamental","pubTime":"2026-08-14 12:50","pubTimestamp":1786683057,"startTime":"0","endTime":"0","summary":"Traders report that the Reserve Bank of India likely stepped into the foreign exchange market on Friday. The move is seen as a response to elevated oil prices and low risk appetite, driven by the...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["INDE","SMIN","GIND","NDIA","FLIN","NFTY","EPI","INDL","INDA","INQQ","IND","PIN","BK4585","IOPP","SCIN","FLIBF","INCO","BK4523","IMVP","INDY","BK4588","TAJX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659195237","title":"Satellos Reports Second Quarter 2026 Financial Results and Highlights Company Progress","url":"https://stock-news.laohu8.com/highlight/detail?id=2659195237","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659195237?lang=en_us&edition=fundamental","pubTime":"2026-08-14 05:02","pubTimestamp":1786654920,"startTime":"0","endTime":"0","summary":"Reported a reduction in muscle fat fraction by MRI along with increased total effort in all TRAILHEAD participants at month six, suggestive of muscle regenerationContinued favorable safety and tolerab","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/08/13/3345007/0/en/satellos-reports-second-quarter-2026-financial-results-and-highlights-company-progress.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4097","BMED","IND","MSLE","BK4139","IDNA","NVIB","PRGS","LU2065732104.USD","GDOC","MEDX","HYLG"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659162993","title":"Press Release: Invivyd Reports Second Quarter 2026 Financial Results and Recent Business Highlights","url":"https://stock-news.laohu8.com/highlight/detail?id=2659162993","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659162993?lang=en_us&edition=fundamental","pubTime":"2026-08-14 04:05","pubTimestamp":1786651500,"startTime":"0","endTime":"0","summary":"-- Achieved Q2 2026 PEMGARDA  net product revenue of $14.3. million, representing 21% growth versus Q2 2025 net product revenue of. -- Completed rapid enrollment in VYD2311 DECLARATION clinical trial. expansion cohort and LIBERTY clinical trial, driven by strong subject. -- DECLARATION pivotal clinical trial enrollment is complete; the ongoing. study is approaching its planned analysis, and in lieu of a Q2 2026. quarterly earnings call, Invivyd plans to hold an investor call post. -- Strong balance sheet with Q2 2026 ending cash and cash equivalents of. $160.1 million anticipated to provide runway through DECLARATION pivotal. data readout and support potential commercial launch readiness for. 30, 2026, compared to $11.8 million in for the quarter ended June 30,-- In July 2026, Invivyd announced receipt of twelve months' advanced notice. of emergency use authorization  termination for PEMGARDA and that. the company is in dialogue with the U.S. Food and Drug Administration.  about approp","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4022","BK4585","NVIB","BK4539","BK4568","BK4548","HYLG","IND","BNTX","BK4588","BK4232","IVVD","IDNA","BK4535","R","BK4551","MEDX","GDOC","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659516286","title":"Eikon Therapeutics Reports Second Quarter 2026 Financial Results and Provides Clinical Updates","url":"https://stock-news.laohu8.com/highlight/detail?id=2659516286","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659516286?lang=en_us&edition=fundamental","pubTime":"2026-08-14 04:02","pubTimestamp":1786651320,"startTime":"0","endTime":"0","summary":"Eikon announced seven abstracts accepted for presentation at the European Society for Medical Oncology (ESMO) Congress 2026 highlighting progress across Eikon’s oncology portfolio, including clinical ","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/08/13/3344893/0/en/eikon-therapeutics-reports-second-quarter-2026-financial-results-and-provides-clinical-updates.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IND","L","BK4588","BK4107","LU0210528500.USD","DMC","BK4189","EIKN","BK4139","BK4135","LU2487616109.SGD","CNS","BK4585","LU0053666078.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659907724","title":"Press Release: Acrivon Reports Second Quarter 2026 Financial Results and Highlights Upcoming 2026 Clinical Data Catalysts","url":"https://stock-news.laohu8.com/highlight/detail?id=2659907724","media":"Dow Jones","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659907724?lang=en_us&edition=fundamental","pubTime":"2026-08-13 04:05","pubTimestamp":1786565100,"startTime":"0","endTime":"0","summary":"Arm 3 with ultra-low dose gemcitabine sensitization) in the. registrational-intent Phase 2b study, across both US and European. -- Two presentations at the American Association for Cancer Research . Annual Meeting highlighted data showing the underlying molecular. mechanisms for potent synergies between ACR-368 and immune checkpoint. AP3. These findings support the potential for clinical combination. studies with antibody-drug conjugates  or ICIs.ACR-2316-- ACR-2316 advanced into the randomized dose expansion stage of the Phase. 1/2 study, supported by observed favorable safety profile and durable. antitumor activity. The expansion phase is evaluating 120 mg and 160 mg. doses, administered orally, once-daily  utilizing a 3d on / 4d off. -- Dose expansion phase will assess safety and activity in subjects with","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["EC","BK4201","BK4139","ACRV","IND"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659907259","title":"Press Release: Longeveron Announces 2026 Second Quarter Financial Results and Provides Business Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2659907259","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659907259?lang=en_us&edition=fundamental","pubTime":"2026-08-13 04:05","pubTimestamp":1786565100,"startTime":"0","endTime":"0","summary":"-- On track for September 2026 top-line results from Phase 2b clinical trial.  evaluating laromestrocel as a potential adjunct treatment for. hypoplastic left heart syndrome , a rare pediatric disease and. -- Longeveron selected as a Finalist and Milestone 2 Awardee for the XPRIZE. Healthspan competition based on published clinical trial results which. indicated laromestrocel increased 6-minute walk distance in patients with. -- Three new independent Directors join Longeveron's Board of Directors. laromestrocel as a potential adjunct therapy for HLHS are anticipated in. -- In May, the Company announced that the U.S. Food and Drug Administration.  held a Type C meeting in late March 2026 focused on the ELPIS II. Phase 2b clinical trial and upcoming data readout.-- Also in May, the Company announced that the independent Data Monitoring. Committee  completed its final prespecified data review for ELPIS II. Phase 2b clinical trial . The DMC performed a risk-benefit. assessment, indicated n","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["AD","NVIB","BK4139","HYLG","IDNA","LGVN","MEDX","BK4081","BK4189","GDOC","DMC","EMA","BK4022","IND","BK4132","BK4232","R"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659185590","title":"Kailera Reports Second Quarter 2026 Financial Results and Provides Business Updates","url":"https://stock-news.laohu8.com/highlight/detail?id=2659185590","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659185590?lang=en_us&edition=fundamental","pubTime":"2026-08-13 04:05","pubTimestamp":1786565100,"startTime":"0","endTime":"0","summary":"IND for ribupatide oral active with U.S. FDA, initiation of global Phase 3 obesity trials planned for the first half of 2027Ribupatide injection Phase 2b high-dose trial in obesity fully enrolled, dat","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/08/12/3344078/0/en/kailera-reports-second-quarter-2026-financial-results-and-provides-business-updates.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IND","BBC","JDOC","PSIL"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659074329","title":"Press Release: ArriVent BioPharma Reports Second Quarter 2026 Financial Results","url":"https://stock-news.laohu8.com/highlight/detail?id=2659074329","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659074329?lang=en_us&edition=fundamental","pubTime":"2026-08-13 04:01","pubTimestamp":1786564860,"startTime":"0","endTime":"0","summary":"-- Topline global pivotal Phase 3 data for firmonertinib in first-line EGFR. -- ARR-217, a CDH17 targeted ADC for gastrointestinal malignancies, advanced. -- Dosing of first patient with ARR-002, a dual-targeting MUC16/NaPi2b. tetravalent ADC with initial focus in ovarian and endometrial cancers. -- Cash and investments of $373.1 million as of June 30, 2026 expected to. Ongoing pivotal Phase 3 study in frontline EGFR exon 20 insertion mutant. NSCLC supported by preclinical data for EGFR inhibitor firmonertinib. showcased high resolution crystal structure data at the 2026 American. Association for Cancer Research  Annual Meeting.Pipeline-- Initiated Phase 1b Dose Optimization of ADC lead ARR-217 .ArriVent has initiated Phase 1b dose optimization for ARR-217, a CDH17. targeted ADC, in patients with gastrointestinal malignancies in. -- Clinically advancing ARR-002 in ovarian and endometrial cancer. ArriVent. the clinic through a first-in-human study evaluating safety, dosing, and. early s","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0456854461.SGD","CRC","BK4080","ADC","BK4231","BK4213","IND","NETL","LU0266512127.USD","BK4139","AVBP"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":10,"pageCount":2,"totalSize":200,"code":"91000000","status":"200"}]}}